巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Akero Therapeutics

    AKRO
    8.820
    0.560
    6.78%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Akero Therapeutics - 延遲價格・最後更新於 27/05 12:14
    最高位
    8.870
    最低位
    8.010
    開市價
    --
    前收市價
    8.260
    成交量(千)
    16.60
    成交額(百萬)
    1.28
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    308.90
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    30.530 - 7.880
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Akero Therapeutics
    證券代碼
    AKRO.US
    所屬板塊
    Biotechnology
    公司業務
    Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.
    發行量
    35022935
    公司總部
    601 Gateway Boulevard, Suite 350
    公司網址
    https://www.akerotx.com
    公司電話
    +1 650 487-6488
    暫無內容

    關於

    Akero Therapeutics(AKRO.US)所屬的行業板塊為Biotechnology。
    Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.
    詳細公司背景可參考: https://www.akerotx.com